Citigroup Inc. Decreases Stock Position in Catalent, Inc. (NYSE:CTLT)

Citigroup Inc. lowered its position in shares of Catalent, Inc. (NYSE:CTLT – Get Rating) by 13.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 81,482 shares of the company’s stock after selling 12,961 shares during the period. Citigroup Inc.’s holdings in Catalent were worth $3,668,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Bellevue Group AG acquired a new position in Catalent during the third quarter worth approximately $34,000. Motco purchased a new stake in Catalent during the third quarter worth $41,000. Eagle Bay Advisors LLC raised its position in Catalent by 138.9% during the fourth quarter. Eagle Bay Advisors LLC now owns 1,254 shares of the company’s stock worth $56,000 after acquiring an additional 729 shares during the last quarter. UMB Bank n.a. raised its position in shares of Catalent by 33.0% during the 4th quarter. UMB Bank n.a. now owns 1,335 shares of the company’s stock worth $60,000 after purchasing an additional 331 shares during the last quarter. Finally, Covestor Ltd lifted its stake in Catalent by 84.9% in the 1st quarter. Covestor Ltd now owns 562 shares of the company’s stock valued at $62,000 after buying an additional 258 shares in the last quarter. Institutional investors and hedge funds own 99.38% of the company’s stock.

Catalent Price Performance

CTLT opened at $37.17 on Monday. Catalent, Inc. has a twelve month low of $31.45 and a twelve month high of $115.33. The company has a current ratio of 1.91, a quick ratio of 1.38 and a debt-to-equity ratio of 0.86. The firm has a market cap of $6.69 billion, a price-to-earnings ratio of 16.45, a PEG ratio of 3.97 and a beta of 1.17. The company has a fifty day simple moving average of $53.08 and a 200 day simple moving average of $53.09.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Morgan Stanley raised their price target on Catalent from $81.00 to $85.00 and gave the stock an “overweight” rating in a research report on Thursday, February 9th. Royal Bank of Canada cut their target price on shares of Catalent from $58.00 to $41.00 in a research note on Monday, May 8th. Deutsche Bank Aktiengesellschaft lowered shares of Catalent from a “buy” rating to a “hold” rating and reduced their target price for the company from $55.00 to $29.00 in a report on Monday, May 15th. Barclays lowered their price target on shares of Catalent from $40.00 to $35.00 in a report on Sunday. Finally, StockNews.com initiated coverage on shares of Catalent in a research note on Thursday. They set a “sell” rating on the stock. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $74.30.

Insider Activity

In related news, insider Manja Boerman sold 1,446 shares of the stock in a transaction dated Monday, May 1st. The stock was sold at an average price of $49.86, for a total value of $72,097.56. Following the completion of the transaction, the insider now owns 14,414 shares of the company’s stock, valued at $718,682.04. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Catalent news, insider Manja Boerman sold 1,446 shares of the stock in a transaction on Monday, May 1st. The shares were sold at an average price of $49.86, for a total transaction of $72,097.56. Following the transaction, the insider now directly owns 14,414 shares in the company, valued at approximately $718,682.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Mario Gargiulo sold 678 shares of the business’s stock in a transaction dated Monday, May 1st. The stock was sold at an average price of $49.86, for a total transaction of $33,805.08. Following the completion of the sale, the senior vice president now directly owns 5,676 shares of the company’s stock, valued at approximately $283,005.36. The disclosure for this sale can be found here. Insiders own 0.58% of the company’s stock.

Catalent Profile

(Get Rating)

Catalent, Inc is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services.